wortmannin-conjugate PI3K/mTOR inhibitors (Wyeth)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namewortmannin-conjugate PI3K/mTOR inhibitors (Wyeth)
Drug Alias NamePWT-458
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth Llc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A